The authors offer bold conclusions: In summary, findings presented herein have profound implications for patients currently considering or taking incretin mimetics for diabetes or weight loss on cancer outcomes. Building on Knowledge These findings, though striking, are not simply a bolt from the blue
Newer medications are designed to activate both GLP-1 and GIP receptors at the same time, which may provide a stronger effect on appetite regulation and metabolic health
Your podcast really helped me see the bigger picture
The Medicines and Healthcare products Regulatory Agency approved semaglutide 25mg tablets (Wegovy) for weight management on 11 June 2026 10
Start at the low end of published ranges, monitor clinical markers and side effects, and only increase gradually if necessary
Research on the Mounjaro and retatrutide trials suggests this typically accounts for around a quarter of total weight loss, similar to whats observed with other forms of significant weight reduction